Figure 2
From: Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens
Combining minimally differentiated T cells and systemic antigen delivery improves tumor control and prolongs survival in two syngeneic mouse cancer models. (A) Schematic illustration of the treatment schedules applied. Tumor growth curves (B,D) and survival plots (C,E) of mice receiving either soluble peptide (SIINFEKL or KVPRNQDWL) and liposomal TLR7/8 stimulation (TMX-201) or liposome antigen delivery (MK062:TMX or MK098:TMX) post T cell infusion. Tumor growth curves (F) and survival plots (G) of mice receiving different liposome formulations post T cell infusion. Tumor growth curves (H) and survival plots (I) of mice receiving dose-matched combination therapy directed against a single antigen or both antigens. Graphs represent pooled averages from three independent experiments with 8 mice pr. group in each experiment. Graphs (B,D,F,H) illustrate mean ± SEM. Survival in (C,D,E,G,I) was calculated by Log-Rank. Difference in mean tumor size on individual days in (B,D,F,H) was calculated using linear mixed model. *P ≤ 0.05, **P ≤ 0.01 ***P ≤ 0.001 ****P ≤ 0.0001.
